Atrix/Fujisawa submit Aczone
This article was originally published in Pharmaceutical Approvals Monthly
Atrix' Aczone (dapsone 5% gel) could clear FDA by mid-2005. Atrix and development partner Fujisawa submitted the NDA for the topical acne treatment Aug. 31 for standard review. Dapsone is currently available only as an oral tablet "due to the compound's water insolubility," Atrix says. Aczone (formerly Atrisone) employs Atrix' proprietary solvent microparticle delivery technology. Aczone is also in early clinicals for treatment of rosacea...
You may also be interested in...
Despite AI and digital analytics playing an increasing role in pharma, the industry lags others globally, a recent event heard. Meanwhile, top Indian players including Sun Pharma, Cipla and others shared what is driving their initiatives, ranging from a 'touchless factory' to virtual training and lessons learned along the way.
Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.
Broader than initially reported, Merck & Co.’s agreement with BARDA extends beyond J&J’s recently authorized vaccine to other COVID-19 vaccines and therapeutics as needed.